Carbamazepine supplier | CasNO.298-46-4

Name
Carbamazepine
EINECS 206-062-7
CAS No. 298-46-4
Article Data34
CAS DataBase
Density 1.266 g/cm³
Solubility insoluble in water
Melting Point 189-192 °C
Formula C₁₅H₁₂N₂O
Boiling Point 410.984 °C at 760 mmHg
Molecular Weight 236.273
Flash Point 202.356 °C
Transport Information
Appearance white solid
Safety 37-24-22-36/37/39-36
Risk Codes 42/43-22-20/21/22
Molecular Structure
Hazard Symbols Xn
Synonyms Geigy 32883;Carbamazepine BP;Carbamazepine Bromine Free;5-Carbamyl-5H-dibenzo(b,f)azepine;Amizepin;Tegretal;Carbamazepine (JP14/USP);G 32883;Lexin;Karbamazepin;G-32883;Neurotol;Finlepsin;5-Carbamoyldibenzo(b,f)azepine;Carbamazepen;Tegretol (TN);5-Carbamoyl-5H-dibenzo(b,f)azepine;Carbazepine;Stazepine;Biston;5H-Dibenz[b,f]azepine-5-carboxamide;
PSA 46.33000
LogP 4.15250

Synthetic route

: 256-96-2
dibenzoazepine

: 917-61-3
sodium isocyanate

: 298-46-4
carbamazepin

Conditions

Conditions	Yield
In water; acetic acid at 15 - 60℃; for 4h; Product distribution / selectivity;	98.8%
In acetic acid at 18 - 60℃; for 5h; Product distribution / selectivity;	95.9%
In ethanol; acetic acid at 60 - 80℃; for 1.5h; Product distribution / selectivity;	93.7%

: 59690-97-0
10-Brom-5-carbamoyl-5H-dibenzazepin

: 298-46-4
carbamazepin

Conditions

Conditions	Yield
With tetraethylammonium perchlorate In water; N,N-dimethyl-formamide cathode: Hg, working potential: -1.80 V, charge: 2.0-2.1 F/mol, 4-5 h;	98%
With tetraethylammonium perchlorate In water; N,N-dimethyl-formamide Mechanism; cathode: Hg, working potential: -1.80 V, charge: 2.0-2.1 F, 4-5 h; other substituted azepines;	98%

: 590-28-3
potassium cyanate

: 256-96-2
dibenzoazepine

: 298-46-4
carbamazepin

Conditions

Conditions	Yield
In water; acetic acid at 20 - 80℃; for 2 - 5.5h; Product distribution / selectivity;	93.2%

: 59690-99-2, 141701-26-0, 143667-56-5
trans-10,11-dibromo-10,11-dihydro-5H-dibenzazepine-5-carboxamide

: 298-46-4
carbamazepin

Conditions

Conditions	Yield
With tetraethylammonium perchlorate In water; N,N-dimethyl-formamide cathode: Hg, working potential: -0.5 V, charge: 1.9-2.1 F/mol, 3-4 h;	92%

: 28721-07-5
oxcarbazepine

: 298-46-4
carbamazepin

Conditions

Conditions	Yield
With methanol; sodium tetrahydroborate at 45 - 50℃; for 3h;	91.5%

: 1189-71-5
isocyanate de chlorosulfonyle

: 256-96-2
dibenzoazepine

: 298-46-4
carbamazepin

Conditions

Conditions	Yield
In dichloromethane; water at 5 - 30℃;	78%

: 143667-55-4
10,11-Dibrom-5-carbamoyl-5H-dibenzazepin

: 298-46-4
carbamazepin

Conditions

Conditions	Yield
With tetraethylammonium perchlorate In N,N-dimethyl-formamide for 12h; cathode: Hg, working potential: -1.35 V, charge: 2.6-3.0 F/mol, initial current density: 0.5 A/dm2;	17%

: 42787-75-7
5-cyanodibenzazepine

: 298-46-4
carbamazepin

Conditions

Conditions	Yield
With hydrogenchloride at 100℃; for 1h; Yield given;
With sulfuric acid; acetic acid In ice-water

: 33948-22-0
5H-dibenz[b,f]azepine-5-carbonylchloride

: 298-46-4
carbamazepin

Conditions

Conditions	Yield
With ammonia In ethanol for 3h; Heating;	5 g
With ammonium hydroxide In methanol at 75 - 85℃; for 5h; Yield given;
Multi-step reaction with 3 steps 1: 78 percent / Br2 / chlorobenzene / 170 °C 2: 90 percent / conc. aq. NH3 / various solvent(s) / 2 h / 100 °C 3: 17 percent / (C2H5)4NClO4 / dimethylformamide / 12 h / cathode: Hg, working potential: -1.35 V, charge: 2.6-3.0 F/mol, initial current density: 0.5 A/dm2 View Scheme

: 52618-28-7, 94063-21-5
carbamazepine cyclobutyl dimer

: 298-46-4
carbamazepin

Conditions

Conditions	Yield
In ethanol Quantum yield; Irradiation;

: 5H-dibenz(b,f)azepine hydrochloride

: 298-46-4
carbamazepin

Conditions

Conditions	Yield
With urea In acetic acid
With urea In acetic acid

: C20H21N3O3S

A: C5H11NO3S

B: 298-46-4
carbamazepin

Conditions

Conditions	Yield
With water at 25℃; Kinetics; Further Variations:; pH-values;

: C17H17N3OS*C2HF3O2

: 298-46-4
carbamazepin

Conditions

Conditions	Yield
With water at 70℃; pH=4; Kinetics; Further Variations:; pH-values; Temperatures;

: 494-19-9
9,10-dihydrodibenzazepine

: 298-46-4
carbamazepin

Conditions

Conditions	Yield
Multi-step reaction with 4 steps 1: 90 percent / toluene / 3.5 h / 90 - 95 °C 2: Br2 / chlorobenzene / 1.5 h / 145 - 150 °C 3: chlorobenzene / 2 h / 150 - 155 °C 4: 25percent NH4OH / methanol / 5 h / 75 - 85 °C View Scheme
Multi-step reaction with 3 steps 1: N-Bromosuccinimide 2: toluene 3: ammonia View Scheme

: 33948-20-8
10-bromo-10,11-dihydro-dibenzo[b,f]azepine-5-carbonyl chloride

: 298-46-4
carbamazepin

Conditions

Conditions	Yield
Multi-step reaction with 2 steps 1: chlorobenzene / 2 h / 150 - 155 °C 2: 25percent NH4OH / methanol / 5 h / 75 - 85 °C View Scheme

: 33948-19-5
10,11-dihydro-dibenzo[b,f]azepine-5-carbonyl chloride

: 298-46-4
carbamazepin

Conditions

Conditions	Yield
Multi-step reaction with 3 steps 1: Br2 / chlorobenzene / 1.5 h / 145 - 150 °C 2: chlorobenzene / 2 h / 150 - 155 °C 3: 25percent NH4OH / methanol / 5 h / 75 - 85 °C View Scheme

: 143667-53-2
10-Brom-5-chlorcarbonyl-5H-dibenzazepin

: 298-46-4
carbamazepin

Conditions

Conditions	Yield
Multi-step reaction with 4 steps 1: 92 percent / (C2H5)4NClO4 / dimethylformamide; H2O / cathode: Hg, working potential: -1.60 V, charge: 2.0-2.1 F/mol, 4-5 h 2: 78 percent / Br2 / chlorobenzene / 170 °C 3: 90 percent / conc. aq. NH3 / various solvent(s) / 2 h / 100 °C 4: 17 percent / (C2H5)4NClO4 / dimethylformamide / 12 h / cathode: Hg, working potential: -1.35 V, charge: 2.6-3.0 F/mol, initial current density: 0.5 A/dm2 View Scheme

Yield

Multi-step reaction with 4 steps
1: 92 percent / (C2H5)4NClO4 / dimethylformamide; H2O / cathode: Hg, working potential: -1.60 V, charge: 2.0-2.1 F/mol, 4-5 h
2: 78 percent / Br2 / chlorobenzene / 170 °C
3: 90 percent / conc. aq. NH3 / various solvent(s) / 2 h / 100 °C
4: 17 percent / (C2H5)4NClO4 / dimethylformamide / 12 h / cathode: Hg, working potential: -1.35 V, charge: 2.6-3.0 F/mol, initial current density: 0.5 A/dm2
View Scheme

: 143667-54-3
10,11-Dibrom-5-chlorcarbonyl-5H-dibenzazepin

: 298-46-4
carbamazepin

Conditions

Conditions	Yield
Multi-step reaction with 2 steps 1: 90 percent / conc. aq. NH3 / various solvent(s) / 2 h / 100 °C 2: 17 percent / (C2H5)4NClO4 / dimethylformamide / 12 h / cathode: Hg, working potential: -1.35 V, charge: 2.6-3.0 F/mol, initial current density: 0.5 A/dm2 View Scheme

: 256-96-2
dibenzoazepine

: 298-46-4
carbamazepin

Conditions

Conditions	Yield
Multi-step reaction with 2 steps 1: CHCl3 / 0.5 h / cooling 2: 10 percent HCl / 1 h / 100 °C View Scheme
Multi-step reaction with 2 steps 1: toluene / 0.5 h 2: 5 g / NH3 (gas) / ethanol / 3 h / Heating View Scheme
With trichloroacetic acid In water; toluene

: 32621-46-8
diphenylamine-2,2'-dicarbonyl chloride

: 298-46-4
carbamazepin

Conditions

Conditions	Yield
Multi-step reaction with 4 steps 1: H2 / Palladium-Barium sulphate; Quinolin sulphate / xylene / 2.5 h / Heating 2: 3.8 g / Hydrazine hydrate / acetic acid / 2 h / Heating 3: toluene / 0.5 h 4: 5 g / NH3 (gas) / ethanol / 3 h / Heating View Scheme

: 49579-63-7
diphenylamine-2,2′-dicarboxaldehyde

: 298-46-4
carbamazepin

Conditions

Conditions	Yield
Multi-step reaction with 3 steps 1: 3.8 g / Hydrazine hydrate / acetic acid / 2 h / Heating 2: toluene / 0.5 h 3: 5 g / NH3 (gas) / ethanol / 3 h / Heating View Scheme

: 579-92-0
Vanadox

: 298-46-4
carbamazepin

Conditions

Conditions	Yield
Multi-step reaction with 5 steps 1: 11.8 g / Thionyl chloride; Pyridine / 5 h / Heating 2: H2 / Palladium-Barium sulphate; Quinolin sulphate / xylene / 2.5 h / Heating 3: 3.8 g / Hydrazine hydrate / acetic acid / 2 h / Heating 4: toluene / 0.5 h 5: 5 g / NH3 (gas) / ethanol / 3 h / Heating View Scheme

: 42787-75-7
5-cyanodibenzazepine

: 7722-84-1
dihydrogen peroxide

: 298-46-4
carbamazepin

Conditions

Conditions	Yield
With sodium bicarbonate In methanol; water

: 256-96-2
dibenzoazepine

monomeric cyanic acid: monomeric cyanic acid

: 298-46-4
carbamazepin

Conditions

Conditions	Yield
With sulfuric acid In nitrogen; ethyl acetate
With acetic acid In nitrogen
In nitrogen; water; acetic acid

: 5H-dibenz(b,f)azepine hydrochloride

: 256-96-2
dibenzoazepine

monomeric cyanic acid: monomeric cyanic acid

: 298-46-4
carbamazepin

Conditions

Conditions	Yield
In nitrogen; toluene
In 5,5-dimethyl-1,3-cyclohexadiene; nitrogen

...Expand

: 256-96-2
dibenzoazepine

: 420-05-3
cyanic acid

: 298-46-4
carbamazepin

Conditions

Conditions	Yield
With hydrogenchloride In nitrogen; ethyl acetate

: 256-96-2
dibenzoazepine

: 506-89-8
urea hydrochloride

: 298-46-4
carbamazepin

Conditions

Conditions	Yield
In acetic acid
In acetic acid

: C25H18N4O7

: 298-46-4
carbamazepin

Conditions

Conditions	Yield
Multi-step reaction with 3 steps 1.1: dicyclohexyl-carbodiimide / tetrahydrofuran; dichloromethane / 6 h / 0 °C / Inert atmosphere 2.1: methylhydrazine / tetrahydrofuran / -80 °C / Inert atmosphere 2.2: 24 h / 20 °C 3.1: 25 °C / pH 5 / aq. buffer View Scheme

: C25H18N4O7

A: 298-46-4
carbamazepin

B: C17H15N3O2

Conditions

Conditions	Yield
Multi-step reaction with 3 steps 1.1: dicyclohexyl-carbodiimide / tetrahydrofuran; dichloromethane / 6 h / 0 °C / Inert atmosphere 2.1: methylhydrazine / tetrahydrofuran / -80 °C / Inert atmosphere 2.2: 24 h / 20 °C 3.1: 25 °C / pH 10 / aq. buffer View Scheme

: 298-46-4
carbamazepin

: 42787-75-7
5-cyanodibenzazepine

Conditions

Conditions	Yield
With bis(trichloromethyl) carbonate In toluene for 5h; Product distribution / selectivity; Reflux;	96%
With sodium hydroxide; Aliquat In chloroform at 20℃; for 70h;	62%
With oxalyl dichloride; dimethyl sulfoxide; triethylamine In dichloromethane at -78 - 20℃;	4%
With sodium hydroxide; N-benzyl-N,N,N-triethylammonium chloride In dichloromethane; chloroform; water at 45 - 50℃; for 5 - 6h;

: 298-46-4
carbamazepin

: 36507-30-9
carbamazepine 10,11-epoxide

Conditions

Conditions	Yield
With peracetic acid; potassium permanganate supported on alumina; sodium carbonate In dichloromethane; acetic acid at 20℃; for 1.66667h; Heating / reflux;	91%
With peroxyacetic acid; potassium permanganate on alumina; sodium carbonate; acetic acid In dichloromethane for 1.66667h; Reflux;	91%
With perpropionic acid; sodium carbonate; acetic acid In dichloromethane at 20℃; for 2h; Reflux;	91%

: 298-46-4
carbamazepin

: 59690-99-2, 141701-26-0, 143667-56-5
trans-10,11-dibromo-10,11-dihydro-5H-dibenzazepine-5-carboxamide

Conditions

Conditions	Yield
With bromine In 1,2-dichloro-ethane for 2h; Ambient temperature;	90%
With bromine In 1,2-dichloro-ethane at 25℃; Rate constant; Mechanism;	100 % Chromat.

: 298-46-4
carbamazepin

: copper(II) choride dihydrate

: [Cu(carbamazepine)2(H2O)2]Cl2*4H2O

Conditions

Conditions	Yield
In ethanol for 3h; Reflux;	88.1%

: 298-46-4
carbamazepin

: 3564-73-6
10,11-Dihydrocarbamazepin

Conditions

Conditions	Yield
With tetraethylammonium perchlorate; ammonium chloride In water; N,N-dimethyl-formamide cathodic (Hg, -2.0 V vs. SCE) reduction;	85%
With tetraethylammonium perchlorate; ammonium chloride In water; N,N-dimethyl-formamide Mechanism; cathodic (Hg, -2.0 V vs. SCE) reduction;	85%
With electrochemical reduction Mechanism; var. pH;

: 298-46-4
carbamazepin

: 256-96-2
dibenzoazepine

Conditions

Conditions	Yield
With tetraethoxy tellurium(IV) In tetrachloromethane for 3h; Heating;	85%
With hydrogenchloride In water for 12h; Reagent/catalyst; Darkness;
With carbon dioxide at 160 - 200℃;

: 298-46-4
carbamazepin

: nickel(II) chloride dihydrate

: [Ni(carbamazepine)2(H2O)2]Cl2*5H2O

Conditions

Conditions	Yield
In ethanol for 3h; Reflux;	85%

: 298-46-4
carbamazepin

: cobalt(II) chloride hexahydrate

: [Co(carbamazepine)2(H2O)2]Cl2*9H2O

Conditions

Conditions	Yield
In ethanol for 3h; Reflux;	84.15%

: 298-46-4
carbamazepin

: 77287-34-4, 77287-35-5, 60100-09-6
formamide

: 139489-10-4
Carbamazepin*Formamid

Conditions

Conditions	Yield
In chloroform	81.5%
In tetrahydrofuran
In methanol

: iron(III) chloride

: 298-46-4
carbamazepin

: 7732-18-5
water

: [Fe(carbamazepine)2(H2O)2]Cl3*5H2O

Conditions

Conditions	Yield
In ethanol for 3h; Reflux;	80.2%

...Expand

: 13520-92-8
ziconium(IV) oxychloride octahydrate

: 298-46-4
carbamazepin

: [ZrO(carbamazepine)2(H2O)]Cl2*8H2O

Conditions

Conditions	Yield
In ethanol for 3h; Reflux;	79.8%

: 298-46-4
carbamazepin

: 109745-70-2, 19757-97-2
methyl glyoxylate methyl hemi-acetal

: 187866-36-0
[(Dibenzo[b,f]azepine-5-carbonyl)-amino]-hydroxy-acetic acid methyl ester

Conditions

Conditions	Yield
In chloroform for 2h; Heating;	78%

Carbamazepine Chemical Properties

IUPAC Name: Benzo[b][1]benzazepine-11-carboxamide
Molecular Formula: C₁₅H₁₂N₂O
Molar mass: 236.27 g/mol
EINECS: 206-062-7
Density: 1.266 g/cm³
Flash Point: 202.4 °C
Index of Refraction: 1.669
Boiling Point: 411 °C at 760 mmHg
Vapour Pressure: 5.78E-07 mmHg at 25 °C
Melting point: 189-192 °C
Storage temp: 2-8 °C
Appearance: White Solid
Solubility: Soluble in Ethanol , Acetone , Propylene glycol , insoluble in water. Odorless, tasteless
Product categories: Acids and Derivatives;Active Pharmaceutical Ingredients;APIs;Intermediates & Fine Chemicals;Heterocycles
Structure of Carbamazepine (CAS NO.298-46-4):

XLogP3-AA: 2.5
H-Bond Donor: 1
H-Bond Acceptor: 1
Canonical SMILES: C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N
InChI: InChI=1S/C15H12N2O/c16-15(18)17-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)
17/h1-10H,(H2,16,18)

Carbamazepine History

Carbamazepine (CAS NO.298-46-4) was discovered by chemist Walter Schindler at J.R. Geigy AG (now part of Novartis) in Basel, Switzerland, in 1953, and was first marketed as a drug to treat trigeminal neuralgia (formerly known as tic douloureux) in 1962. It has been approved in the U.S. since 1974. Carbamazepine would be studied for bipolar disorder throughout the 1970s.

Carbamazepine Uses

Carbamazepine (CAS NO.298-46-4) is an anticonvulsant and mood stabilizing drug used primarily in the treatment of epilepsy and bipolar disorder, as well as trigeminal neuralgia. It is also used off-label for a variety of indications, including schizophrenia, attention-deficit hyperactivity disorder (ADHD), paroxysmal extreme pain disorder, phantom limb syndrome, and post-traumatic stress disorder.

Carbamazepine Toxicity Data With Reference

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
child	TDLo	oral	19mg/kg/4W-I (19mg/kg)	PERIPHERAL NERVE AND SENSATION: FASCICULATIONS	Pediatrics. Vol. 73, Pg. 841, 1984.
child	TDLo	oral	25926ug/kg (25.926mg/kg)	BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD	Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 35, Pg. 320, 1993.
child	TDLo	oral	55mg/kg (55mg/kg)	BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD BEHAVIORAL: COMA	Journal of Toxicology, Clinical Toxicology. Vol. 38, Pg. 323, 2000.
child	TDLo	oral	65mg/kg (65mg/kg)	BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD BEHAVIORAL: COMA LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES	Journal of Pediatrics. Vol. 121, Pg. 295, 1992.
child	TDLo	oral	420mg/kg/3W-I (420mg/kg)	SENSE ORGANS AND SPECIAL SENSES: OTHER: EYE BEHAVIORAL: TREMOR BEHAVIORAL: GENERAL ANESTHETIC	Journal of Toxicology, Clinical Toxicology. Vol. 36, Pg. 109, 1998.
child	TDLo	oral	1050mg/kg/6W- (1050mg/kg)	BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY)	American Journal of Psychiatry. Vol. 143, Pg. 1176, 1985.
dog	LD50	oral	5620mg/kg (5620mg/kg)		"Psychotropic Drugs and Related Compounds," 2nd ed., Usdin, E., and D.H. Efron, Washington, DC, 1972Vol. -, Pg. 63, 1972.
guinea pig	LD50	oral	920mg/kg (920mg/kg)		"Psychotropic Drugs and Related Compounds," 2nd ed., Usdin, E., and D.H. Efron, Washington, DC, 1972Vol. -, Pg. 63, 1972.
human	TDLo	oral	43mg/kg (43mg/kg)	BEHAVIORAL: SLEEP BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS" GASTROINTESTINAL: NAUSEA OR VOMITING	British Medical Journal. Vol. 1, Pg. 754, 1977.
man	LDLo	oral	54mg/kg/9D-I (54mg/kg)	BEHAVIORAL: ATAXIA KIDNEY, URETER, AND BLADDER: URINE VOLUME INCREASED BLOOD: AGRANULOCYTOSIS	Canadian Medical Association Journal. Vol. 132, Pg. 1040, 1985.
man	TDLo	oral	94mg/kg/11D-I (94mg/kg)	BLOOD: THROMBOCYTOPENIA	Journal of Clinical Pyschopharmacology. Vol. 10, Pg. 305, 1990.
man	TDLo	oral	160mg/kg/3W-I (160mg/kg)	SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE"	Journal of Clinical Pyschopharmacology. Vol. 5, Pg. 185, 1985.
man	TDLo	oral	253mg/kg/6W-I (253mg/kg)	GASTROINTESTINAL: NAUSEA OR VOMITING LIVER: LIVER FUNCTION TESTS IMPAIRED	Journal of Clinical Pyschopharmacology. Vol. 6, Pg. 251, 1986.
mouse	LD50	intraperitoneal	114mg/kg (114mg/kg)		Farmakologiya i Toksikologiya Vol. 53(4), Pg. 19, 1990.
mouse	LD50	oral	529mg/kg (529mg/kg)		Farmaco. Vol. 44, Pg. 595, 1989.
mouse	LD50	subcutaneous	> 1gm/kg (1000mg/kg)		Arzneimittel-Forschung. Drug Research. Vol. 30, Pg. 477, 1980.
rabbit	LD50	oral	2680mg/kg (2680mg/kg)		"Psychotropic Drugs and Related Compounds," 2nd ed., Usdin, E., and D.H. Efron, Washington, DC, 1972Vol. -, Pg. 63, 1972.
rat	LD50	intraperitoneal	158mg/kg (158mg/kg)		Archives Internationales de Pharmacodynamie et de Therapie. Vol. 202, Pg. 106, 1973.
rat	LD50	oral	1957mg/kg (1957mg/kg)	BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)	Japanese Kokai Tokyo Koho Patents. Vol. #79-163823,
rat	LD50	subcutaneous	> 1500mg/kg (1500mg/kg)		Arzneimittel-Forschung. Drug Research. Vol. 30, Pg. 477, 1980.
women	LDLo	oral	1920mg/kg/17W (1920mg/kg)	BLOOD: APLASTIC ANEMIA	American Journal of Psychiatry. Vol. 142, Pg. 974, 1985.
women	TDLo	oral	28mg/kg/4D-I (28mg/kg)	BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) GASTROINTESTINAL: NAUSEA OR VOMITING	American Journal of Psychiatry. Vol. 143, Pg. 1328, 1986.
women	TDLo	oral	112mg/kg/2W-I (112mg/kg)	GASTROINTESTINAL: NAUSEA OR VOMITING BLOOD: THROMBOCYTOPENIA	American Journal of Psychiatry. Vol. 150, Pg. 1750, 1993.
women	TDLo	oral	144mg/kg/2W-I (144mg/kg)	BLOOD: THROMBOCYTOPENIA SKIN AND APPENDAGES (SKIN): "DERMATITIS, ALLERGIC: AFTER SYSTEMIC EXPOSURE"	Journal of Clinical Psychiatry. Vol. 53, Pg. 378, 1992.
women	TDLo	oral	560mg/kg/4W-I (560mg/kg)	BLOOD: CHANGES IN BONE MARROW NOT INCLUDED ABOVE	British Journal of Clinical Practice. Vol. 43, Pg. 302, 1989.
women	TDLo	oral	7604mg/kg/69W (7604mg/kg)	BEHAVIORAL: GENERAL ANESTHETIC CARDIAC: EKG CHANGES NOT DIAGNOSTIC OF ABOVE	Japanese Heart Journal. Vol. 39, Pg. 469, 1998.

Carbamazepine Safety Profile

Hazard Codes: Harmful Xn
Risk Statements: 42/43-22-20/21/22
R20/21/22:Harmful by inhalation, in contact with skin and if swallowed.
R22:Harmful if swallowed.
R42/43:May cause sensitization by inhalation and skin contact.
Safety Statements: 37-24-22-36/37/39-36
S22:Do not breathe dust.
S24:Avoid contact with skin.
S36:Wear suitable protective clothing.
S37:Wear suitable gloves.
S36/37/39:Wear suitable protective clothing, gloves and eye/face protection.

Carbamazepine Specification

Carbamazepine ,its cas register number is 298-46-4. It can be called Finlepsin and Tegretol . And it has been sold under the names Biston, Tegretol, Calepsin, Equetro, Finlepsin, Sirtal, Carbatrol, Epitol, Stazepine, Telesmin, Teril, Trimonil, Timonil, Epimaz, Amizepin (Poland), Hermolepsin (Sweden), Carbama/Carbamaze (New Zealand), and Degranol (South Africa).

Product Name

Carbamazepine

Synthetic route

Carbamazepine Chemical Properties

Carbamazepine History

Carbamazepine Uses

Carbamazepine Toxicity Data With Reference

Carbamazepine Safety Profile

Carbamazepine Specification

Related Products

Hot Products